Αρχική World News Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on... World News Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms Από Ogkologos - 6 Αυγούστου, 2025 669 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SAVANNAH study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers 15 Νοεμβρίου, 2023 ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk... 21 Μαΐου, 2026 EMA Recommends Granting a Marketing Authorisation for Lazertinib 4 Δεκεμβρίου, 2024 What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials 6 Δεκεμβρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS The path to least resistance: How our researchers are outsmarting cancer’s... EMA Recommends Extension of Indications for Osimertinib COVID Vaccine Basics for Cancer Patients 2026 Heine H. Hansen Award Recipient Announced